Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Revive Therapeutics Ltd.

Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:PHRM CSE:RVV PHRRF RVVTF
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:PHRM CSE:RVV PHRRF RVVTF
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Corporate Update
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.